Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience
Vedolizumab (VDZ) has been used for induction of remission in inflammatory bowel diseases (IBD) At week 52, the response was observed in 62/133 (46.7%) CD patients, including 28 (21%) in clinical remission.
